A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies

Trial Profile

A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2018

At a glance

  • Drugs Inebilizumab (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 21 May 2018 Planned End Date changed from 28 Sep 2018 to 28 Dec 2018.
    • 21 May 2018 Planned primary completion date changed from 28 Sep 2018 to 28 Dec 2018.
    • 30 Jan 2018 Planned End Date changed from 14 Jun 2018 to 28 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top